FrancophonIA/ELRC3.0 huggingface dataset:
English: For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Capecitabine Accord are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjusment according to toxicity.
Slovenian: Bolnike z delnim pomanjkanjem DPD (kot so tisti s heterozigotnimi mutacijami v genu DPYD) za katere smatramo, da koristi zdravila Kapecitabin Accord odtehtajo tveganja (upoštevaje primernost druge ne-fluoropirimidinske sheme kemoterapije), je treba zdraviti izredno previdno in jih pogosto spremljati ter prilagoditi odmerek glede na toksičnost.
English: Elderly: Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU.
Slovenian: Starejši bolniki: na osnovi podatkov populacijske farmakokinetične študije, ki je zajela bolnike z velikim razponom v letih (27 do 86 let) in 234 bolnikov (46 %), starih 65 let ali starejših, so ugotovili, da starost ne vpliva na farmakokinetiko 5'-DFUR in 5-FU.
English: You must inform your doctor if you know that you have an allergy or over-reaction to this medicine,
Slovenian: Če veste, da ste alergični na kapecitabin ali imate preobčutljivostno reakcijo na to zdravilo,
English: • Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.
Slovenian: • Stevens-Johnsonov sindrom: če dobite boleč, rdeč ali škrlaten izpuščaj, ki se širi ali se začnejo pojavljati mehurji in/ali druge poškodbe na sluznici (npr. v ustih in na ustnicah), še posebno, če ste bili občutljivi na svetlobo ali imeli okužbe dihal (npr. bronhitis) in/ali zvišano telesno temperaturo.
English: What Capecitabine Accord is and what it is used for What you need to know before you take Capecitabine Accord How to take Capecitabine Accord Possible side effects
Slovenian: Kaj je zdravilo Kapecitabin Accord in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Kapecitabin Accord Kako jemati zdravilo Kapecitabin Accord
English: 30 film-coated tablets 60 film-coated tablets 120 film-coated tablets 30 x 1 film-coated tablets 60 x 1 film-coated tablets 120 x 1 film-coated tablets
Slovenian: 30 filmsko obloženih tablet 60 filmsko obloženih tablet 120 filmsko obloženih tablet 30 x 1 filmsko obloženih tablet 60 x 1 filmsko obloženih tablet 120 x 1 filmsko obloženih tablet
English: If you take more Capecitabine Accord than you should
Slovenian: Če ste vzeli večji odmerek zdravila Kapecitabin Accord, kot bi smeli
English: Table 8 Key efficacy results for the non-inferiority analysis of Study NO16966
Slovenian: Glavni rezultati o učinkovitosti za analizo ne-inferiornosti v študiji NO16966
English: Table 3 Capecitabine dose reduction schedule (3-weekly cycle or continuous treatment).
Slovenian: Shema za zmanjšanje odmerka pri zdravljenju s kapecitabinom (3-tedenski cikli ali neprekinjeno zdravljenje)
English: If the calculated creatinine clearance decreases during treatment to a value below 30 ml/min, Capecitabine Accord should be discontinued.
Slovenian: Če se izračunani kreatininski očistek med zdravljenjem zmanjša pod 30 ml/min, je treba zdravljenje z zdravilom kapecitabin ukiniti.
English: Parameter: Progression-free Survival
Slovenian: Parameter: Preživetje brez napredovanja bolezni
English: Hepatic failure (rare), Cholestatic hepatitis (rare)
Slovenian: (redki), holestatični hepatitis (redki)
English: See also section “Do not take Capecitabine Accord”.
Slovenian: Glejte tudi poglavje “Ne jemljite zdravila Kapecitabin
English: Do not drive if you feel dizzy, nauseous or tired after taking this medicine.
Slovenian: Če ste omotični, vam je slabo ali ste po zaužitju zdravila utrujeni, ne vozite.
English: Table 10 Key efficacy results for the non-inferiority analysis of Study NO16967
Slovenian: Glavni rezultati o učinkovitosti za analizo ne-inferiornosti v študiji NO16967.
English: • severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes).
Slovenian: • hude kožne reakcije, kot so kožni izpuščaj, razjede in mehurji, ki lahko vključujejo razjede v ustih, nosu, na spolovilih, rokah, nogah in v očeh (rdeče in zatekle oči).
English: • Medicines used to treat folic acid deficiency.
Slovenian: • zdravil za zdravljenje pomanjkanja folne kisline.
English: Interrupt until resolved to grade 0-1 100%
Slovenian: • Stopnja 2 - 1. pojav prekinitev, dokler ni dosežena stopnja 0−1 100 %
English: Capecitabine Accord contains capecitabine, which itself is not a cytostatic medicine.
Slovenian: Zdravilo Kapecitabin Accord vsebuje kapecitabin, ki sam nima citostatičnega učinka.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Slovenian: Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.Če ste noseči ali če obstaja sum na nosečnost, zdravila Kapecitabin Accord ne smete jemati.
English: Dihydropyrimidine dehydrogenase (DPD) deficiency Rarely, unexpected, severe toxicity (e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-FU has been attributed to a deficiency of DPD activity.
Slovenian: Redko, nepričakovano, hudo toksičnost (npr. stomatitis, drisko, vnetje sluznic, nevtropenijo in nevrotoksičnost), povezano s 5-FU, pripisujemo pomanjkanju aktivnosti DPD.
English: When capecitabine was used in combination with other medicinal products, elderly patients (≥65 years) experienced more grade 3 and grade 4 adverse drug reactions, including those leading to discontinuation, compared to younger patients.
Slovenian: Kadar so zdravilo kapecitabin uporabljali z drugimi zdravili, so imeli starejši bolniki (stari 65 let ali več) v primerjavi z mlajšimi več neželenih učinkov stopnje 3 in 4, vključno s tistimi, ki so povzročili ukinitev zdravila.
English: Diabetes mellitus or electrolyte disturbances
Slovenian: Sladkorna bolezen ali elektrolitske motnje:
English: Patients with renal impairment: Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU.
Slovenian: Bolniki z ledvično okvaro: glede na farmakokinetično študijo pri bolnikih, ki imajo blago do hudo ledvično okvaro, ni dokazov za vpliv kreatininskega očistka na farmakokinetiko zdravila in 5-FU.
English: • infections of the lungs or respiratory tract system (e.g. pneumonia or bronchitis)
Slovenian: • vnetje pljuč ali dihalnih poti (npr. pljučnico ali bronhitis),
English: If you have an unrecognised DPD deficiency and take Capecitabine Accord, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.
Slovenian: Če ne veste, da imate pomanjkanje DPD in vzamete zdravilo Kapecitabin Accord, imate večje tveganje za nenaden, zgodnji pojav hudih oblik neželenih učinkov, navedenih v poglavju 4.
English: Each pack contains 30, 60 or 120 film-coated tablets.
Slovenian: Vsako pakiranje vsebuje 30, 60 ali 120 filmsko obloženih tablet.
English: If no toxicity is observed in patients ≥60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m2 twice daily.
Slovenian: Če se pri bolnikih, starih 60 let ali več, med zdravljenjem z zmanjšanim odmerkom zdravila kapecitabin v kombinaciji z docetakselom toksičnost ne pojavi, lahko odmerek zdravila kapecitabin previdno zvečamo na 1.250 mg/m2 dvakrat na dan.
English: In patients with unrecognised DPD deficiency treated with capecitabine, as well as in those patients who test negative for specific DPYD variations ,life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
Slovenian: Pri bolnikih, pri katerih pomanjkanje DPD ni znano , kot tudi pri bolnikih z negativnim testom za specifične spremembe gena DPYD,ki jih zdravimo s kapecitabinom, se lahko pojavijo življensko ogrožujoče toksičnosti, ki se izrazijo kot akutno prekomerno odmerjanje (glejte poglavje 4.9).
English: Patients with hepatic impairment due to liver metastases: According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment.
Slovenian: Bolniki z jetrno okvaro zaradi zasevkov v jetrih: glede na farmakokinetično študijo pri bolnikih z rakom, ki imajo blago ali zmerno jetrno okvaro zaradi zasevkov v jetrih, je biološka uporabnost kapecitabina in izpostavljenost 5-FU lahko povečana v primerjavi z bolniki brez okvare.
English: Do not give Capecitabine Accord to children and adolescent.
Slovenian: Otrokom in mladostnikom ne dajajte zdravila Kapecitabin Accord.
English: Table 5 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1900 patients (studies M66001, SO14695, and SO14796).
Slovenian: Preglednica 5 našteva neželene učinke, povezane s samostojnim zdravljenjem s kapecitabinom, ki so jih zbrali z analizo podatkov o varnosti v treh glavnih kliničnih študijah pri več kot 1.900 bolnikih (študije M66001, SO14695 in SO14796).
English: The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10) uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Slovenian: Neželeni učinki so razvrščeni po njihovi pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni
English: In a interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin.
Slovenian: V raziskavi interakcij z zdravili so pri jemanju enkratnega odmerka varfarina ugotovili pomembno povečanje povprečne AUC S-varfarina (+ 57 %).
English: Table 6 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients.
Slovenian: Preglednica 6 našteva neželene učinke, povezane z uporabo kapecitabina v kombinaciji z različnimi kemoterapijami pri več indikacijah, ki temeljijo na podatkih o varnosti, zbranih pri več kot 3.000 bolnikih.
English: Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as these may be aggravated during capecitabine treatment.
Slovenian: Pri bolnikih s sladkorno boleznijo ali elektrolitskimi motnjami je potrebna previdnost, ker se njihovo stanje lahko poslabša.
English: Capecitabine Accord should only be prescribed by a doctor experienced in the use of anticancer medicines.
Slovenian: Zdravilo Kapecitabin Accord lahko predpiše samo zdravnik, usposobljen za uporabo zdravil proti raku.
English: The pooled analysis includes 3097 patients treated with capecitabine -containing regimens and 3074 patients treated with 5-FU-containing regimens.
Slovenian: Skupna analiza je zajela 3.097 bolnikov, katerih zdravljenje je vključevalo kapecitabin, in 3.074 bolnikov, katerih zdravljenje je vključevalo 5-FU.
English: ITT 95% CI
Slovenian: 95-% CI
English: Method of administration Capecitabine Accord tablets should be swallowed with water within 30 minutes after a meal.
Slovenian: Filmsko obložene tablete zdravila Kapecitabin Accord je treba pogoltniti z vodo največ 30 minut po obroku.
English: • In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD)
Slovenian: • Pri bolnikih z znano popolno odsotnostjo aktivnosti dihidropirimidin dehidrogenaze (DPD)
English: • blood-thinning medicines (coumarin, warfarin),
Slovenian: • zdravil proti strjevanju krvi (kumarinov, varfarina),
English: Phenytoin
Slovenian: Fenitoin:
English: in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Slovenian: - v kombinaciji z docetakselom (glejte poglavje 5.1) zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešni citotoksični kemoterapiji.
English: Number of 150 mg tablets, 300 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening)
Slovenian: Število 150-mg tablet, 300mg tablet in/ali 500-mg tablet za posamezno dajanje (zdravilo se daje zjutraj in zvečer)
English: • radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab,
Slovenian: • radioterapije in nekaterih zdravil za zdravljenje raka (folinske kisline, oksaliplatina,
English: • have calcium imbalances (seen in blood tests)
Slovenian: • imate porušeno ravnovesje kalcija (razvidno iz krvnih preiskav),
English: You might get the following side effects if you take a lot more capecitabine than you should, feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells).
Slovenian: Če ste vzeli veliko večji odmerek kapecitabina, kot bi smeli, vas lahko prizadenejo naslednji neželeni učinki: slabost ali bruhanje, driska, vnetje ali razjede v črevesu ali ustih, bolečina ali krvavitev iz črevesa oziroma želodca ali zavrtje kostnega mozga (zmanjšanje števila določenih krvnih celic).
English: When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand-foot syndrome, because of published reports that it may decrease the efficacy of cisplatin.
Slovenian: Kadar zdravilo Kapecitabin Accord in cisplatin uporabljamo v kombinaciji, ni priporočljiva uporaba vitamina B6 (piridoksina) za simptomatično ali sekundarno profilaktično zdravljenje sindroma roka-noga.
English: The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis.
Slovenian: FU zavira tudi sintezo RNA in proteinov.
English: How to store Capecitabine Accord Contents of the pack and other information
Slovenian: Shranjevanje zdravila Kapecitabin Accord Vsebina pakiranja in dodatne informacije
English: If these side effects continue, contact your doctor immediately.
Slovenian: Če se pojavijo, se takoj posvetujte z zdravnikom.
English: The following factors were pre-specified in the statistical analysis plan for inclusion in the model: age, time from surgery to randomisation, gender, CEA levels at baseline, lymph nodes at baseline, and country.
Slovenian: V načrtu statistične analize so bili za vključitev v model vnaprej določeni naslednji dejavniki: starost, čas od operacije do randomizacije, spol, izhodiščna vrednost karcinoembrionalnega antigena (CEA), izhodiščno stanje bezgavk, država.
English: If you stop taking Capecitabine Accord
Slovenian: Če ste prenehali jemati zdravilo Kapecitabin Accord
English: Further catalytic activation of 5'-DFUR then occurs by thymidine phosphorylase (ThyPase).
Slovenian: Nadaljnja katalitska aktivacija 5'DFUR poteka s timidin fosforilazo.
English: Patients treated with XELIRI + bevacizumab reported a significantly higher incidence of diarrhoea, febrile neutropenia and hand-foot skin reactions than patients treated with FOLFIRI + bevacizumab with significantly increased treatment delays, dose reductions and treatment discontinuations.
Slovenian: zdravljenih s XELIRI + bevacizumabom, so poročali o signifikantno večji incidenci driske, febrilne nevtropenije in kožnih reakcij roka-noga kot pri bolnikih, zdravljenih s FOLFIRI + bevacizumabom.
English: Capecitabine Accord contains lactose
Slovenian: Zdravilo Kapecitabin Accord vsebuje laktozo
English: Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible patient population and the intent-to-treat population (see Table 8).
Slovenian: Ne-inferiornost zdravljenja, ki vsebuje XELOX v primerjavi z zdravljenjem, ki vsebuje FOLFOX-4 v celokupni primerjavi, je bila dokazana glede na preživetje brez napredovanja bolezni v primerni populaciji bolnikov in populaciji bolnikov, ki so jo nameravali zdraviti (glejte preglednico 8).
English: In repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines.
Slovenian: 5.3 Predklinični podatki o varnosti V študijah toksičnosti pri ponavljajočih se odmerkih je dnevno jemanje kapecitabina pri opicah cynomolgus in miših povzročilo toksične učinke na gastrointestinalni, limfni in krvni sistem, ki so sicer tipični za fluoropirimidine.
English: ITT *PPP=per-protocol population; **ITT=intent-to-treat population.
Slovenian: ITT *PPP = populacija po protokolu (per-protocol population); **ITT = populacija, ki so jo nameravali zdraviti (intent-to-treat population), CI = interval zaupanja (confidence interval) Napredovali rak želodca:
English: The study contained two parts: an initial 2-arm part in which 634 patients were randomised to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomised to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab, and FOLFOX-4 plus bevacizumab.
Slovenian: Študija je bila sestavljena iz dveh delov: začetnega dela iz dveh skupin, v katerem so 634 bolnikov randomizirali v dve različni skupini zdravljenja, po shemi XELOX ali shemi FOLFOX-4, in poznejšega dela s faktorskim načrtom2x2 v katerem so 1.401 bolnika randomizirali v štiri različne skupine zdravljenja, XELOX in placebo,
English: In a preplanned multivariate Cox analysis, superiority of capecitabine compared with bolus 5-FU/LV was demonstrated.
Slovenian: Coxovi analizi so dokazali superiornost kapecitabina v primerjavi s 5-FU/LV v obliki bolusa.
English: Hypo- or hypercalcaemia
Slovenian: Hipokalciemija ali hiperkalciemija:
English: XELOX + bevacizumab (ITT: N=127)
Slovenian: shema XELOX + bevacizumab (ITT: n = 127)
English: Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus(e.g. DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants), which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of lifethreatening or fatal toxicity and should not be treated with Capecitabine Accord (see section 4.3).
Slovenian: Čeprav pomanjkanja DPD ne moremo natančno določiti, je znano, da imajo bolniki z določenimi homozigotnimi ali določenimi sestavljenimi heterozigotnimi mutacijami v lokaciji gena DPYD (npr. z različicami DPYD*2A, c.1679T>G, c.2846A>T in c.1236G>A/HapB3), ki lahko povzročijo popolno ali skoraj popolno pomanjkanje encimske aktivnosti DPD (določene z laboratorijskim testom),
English: • medicines for seizures or tremors (phenytoin)
Slovenian: • zdravil za preprečevanje epileptičnih napadov ali tremorja (fenitoin)
English: Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.
Slovenian: ki so prejemali 1.250 mg/m2 kapecitabina dvakrat na dan. Spol, prisotnost ali odsotnost zasevkov v jetrih, splošno bolnikovo stanje, celokupni bilirubin, serumski albumin, AST in ALT niso statistično značilno vplivali na farmakokinetiko 5'-DFUR, 5-FU in FBAL.
English: If you are a male patient and your female partner could become pregnant, you should use effective contraception during treatment with Capecitabine Accord and for 3 months after the last dose.
Slovenian: Če ste bolnik in bi vaša partnerka lahko zanosila, morate med zdravljenjem z zdravilom Kapecitabin Accord in še 3 mesece po zadnjem odmerku zdravila uporabljati učinkovito kontracepcijo.
English: Each pack contains 30 x 1, 60 x 1 or 120 x 1 film-coated tablets.
Slovenian: Vsako pakiranje vsebuje 30 x 1, 60 x 1 ali 120 x 1 filmsko obloženih tablet.
English: The median follow up at the time of the primary analyses in the intent-to-treat population was 1.5 years; data from analyses following an additional 1 year of follow up are also included in Table 8.
Slovenian: ki so jo nameravali zdraviti, je bila 1,5 leta; podatki iz analize po dodatnem enoletnem spremljanju so prav tako vključeni v preglednico 8.
English: Capecitabine Accord is available in blister packs containing 30, 60 or 120 film-coated tablets or in perforated unit dose blister packs containing 30 x 1, 60 x 1 or 120 x 1 film-coated tablets.
Slovenian: Zdravilo Kapecitabin Accord je na voljo v pretisnih omotih po 30, 60 ali 120 filmsko obloženih tablet ali v perforiranih pretisnih omotih za enkratni odmerek po 30 x 1, 60 x 1 ali 120 x 1 filmsko obloženih tablet.
English: Aluminium/aluminium or PVC/PVdC/Aluminium blister containing 30, 60 or 120 film-coated tablets.
Slovenian: Aluminijevi/aluminijevi ali PVC/PVdC/aluminijevi pretisni omoti v pakiranju po 30, 60 ali 120 filmsko obloženih tablet.
English: In this trial, 1002 patients were randomised in a 2x2 factorial design to one of the following 4 arms:
Slovenian: bolnika randomizirana v eno od naslednjih štirih skupin po 2x2 faktorskem načrtu:
English: (neuropathy)
Slovenian: (nevropatija),
English: PRIMARY ANALYSIS XELOX/ XELOX+P/ XELOX+BV (EPP*: N=967; ITT**: N=1017)
Slovenian: OSNOVNA ANALIZA XELOX/XELOX + P/ XELOX + BEVACIZUMAB (EPP*: n = 967; ITT**: n =
English: If you get any side effects, talk to your doctor or pharmacist or nurse.
Slovenian: Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom, farmacevtom ali medicinsko sestro.
English: For the dosing schedule of XELOX and FOLFOX-4 (without addition of placebo or bevacizumab), refer to Table 7.
Slovenian: Odmerjanje zdravljenja po shemah XELOX in FOLFOX-4 (brez dodatka placeba ali bevacizumaba) je opisano v preglednici 7.
English: Anhydrous lactose Microcrystalline cellulose (E460) Croscarmellose sodium Hypromellose (E5) Magnesium stearate
Slovenian: Jedro tablete brezvodna laktoza mikrokristalna celuloza (E460) premrežen natrijev karmelozat hipromeloza (E5) magnezijev stearat
English: At the dose of 1250 mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in µg/ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.
Slovenian: 1.250 mg/m2 ob jemanju po obroku so bile na 14. dan največje plazemske koncentracije (Cmax v μg/ml) za kapecitabin, 5'-DFCR, 5'-DFUR, 5-FU in FBAL 4,67; 3,05; 12,1; 0,95 in 5,46.
English: Palmar-plantar erythrodysaesthesia syndrome**
Slovenian: Bolezni kože in podkožja palmarnoplantarna eritrodisestezija**
English: • gout medicines (allopurinol),
Slovenian: • zdravil proti protinu (alopurinola),
English: 820 Patients were randomised to receive either sequential treatment (n=410) or combination treatment (n=410).
Slovenian: V skupino, ki je prejela zaporedno zdravljenje (n = 410) in skupino, ki je prejela kombinacijo zdravil (n = 410), so randomizirali 820
English: There is no data on capecitabine and impact on fertility.
Slovenian: Plodnost Podatkov o vplivu kapecitabina na plodnost ni.